Cantor Fitzgerald Estimates SLDB FY2025 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Solid Biosciences in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will earn ($2.45) per share for the year. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.12).

A number of other research analysts have also recently commented on SLDB. Citizens Jmp upgraded shares of Solid Biosciences to a “strong-buy” rating in a research note on Tuesday, December 10th. JMP Securities assumed coverage on shares of Solid Biosciences in a research note on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Solid Biosciences in a research report on Friday, January 10th. Truist Financial assumed coverage on Solid Biosciences in a research report on Wednesday, January 8th. They issued a “buy” rating and a $16.00 target price on the stock. Finally, JPMorgan Chase & Co. decreased their price target on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Tuesday, November 12th. Nine equities research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $15.30.

Solid Biosciences Stock Performance

NASDAQ:SLDB opened at $3.26 on Wednesday. The stock’s 50 day moving average price is $4.56 and its 200 day moving average price is $6.49. Solid Biosciences has a 52 week low of $3.03 and a 52 week high of $15.05.

Insiders Place Their Bets

In related news, COO David T. Howton sold 5,072 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $28,403.20. Following the completion of the transaction, the chief operating officer now directly owns 15,663 shares of the company’s stock, valued at $87,712.80. This represents a 24.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jessie Hanrahan sold 4,610 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $25,816.00. Following the completion of the transaction, the insider now owns 14,235 shares of the company’s stock, valued at approximately $79,716. The trade was a 24.46 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 25,925 shares of company stock valued at $136,853 over the last quarter. 13.63% of the stock is owned by corporate insiders.

Institutional Trading of Solid Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC lifted its position in Solid Biosciences by 412.1% in the 3rd quarter. Barclays PLC now owns 62,856 shares of the company’s stock valued at $439,000 after acquiring an additional 50,582 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Solid Biosciences during the 3rd quarter valued at $121,000. Wellington Management Group LLP lifted its position in shares of Solid Biosciences by 183.6% in the third quarter. Wellington Management Group LLP now owns 119,804 shares of the company’s stock valued at $835,000 after acquiring an additional 77,564 shares in the last quarter. State Street Corp grew its holdings in Solid Biosciences by 9.2% during the 3rd quarter. State Street Corp now owns 441,540 shares of the company’s stock valued at $3,078,000 after buying an additional 37,130 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Solid Biosciences by 292.8% in the third quarter. Point72 Asset Management L.P. now owns 443,010 shares of the company’s stock worth $3,088,000 after buying an additional 330,234 shares in the last quarter. 81.46% of the stock is owned by hedge funds and other institutional investors.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.